Show simple item record

dc.contributor.authorDagli, Ulku
dc.contributor.authorKalkan, Ismail Hakki
dc.date.accessioned2019-06-01T14:52:36Z
dc.date.available2019-06-01T14:52:36Z
dc.date.issued2017
dc.identifier.issn1300-4948
dc.identifier.urihttp://www.turkjgastroenterol.org/sayilar/303/buyuk/S53-S56.pdf
dc.identifier.urihttp://hdl.handle.net/11727/3379
dc.description.abstractGastroesophageal reflux disease (GERD) is frequently seen during pregnancy. In the medical treatment of pregnant women with GERD, alginic acid and sucralfate can be used. Calcium- and magnesium-based antacids can also be used, particularly for patients with preeclampsia. In particular, ranitidine -a histamine-2 receptor blocker-is preferred. In the case of non-responsiveness to the abovementioned treatments, proton pump inhibitors (PPIs), except omeprazole, can be given considering the benefit-harm ratio for the mother and fetus after the first trimester. In cases with GERD during the lactation period, drugs having minimum systemic absorption, such as sucralfate and alginic acid, are preferable but there is no data.en_US
dc.language.isoengen_US
dc.relation.isversionof10.5152/tjg.2017.14en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRefluxen_US
dc.subjectPregnancyen_US
dc.subjectSafetyen_US
dc.titleTreatment of reflux disease during pregnancy and lactationen_US
dc.typearticleen_US
dc.relation.journalTURKISH JOURNAL OF GASTROENTEROLOGYen_US
dc.identifier.volume28en_US
dc.identifier.startpageS53en_US
dc.identifier.endpageS56en_US
dc.identifier.wos000417204500013


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record